Drug Patents owned by Janssen Prods

1. List of Edurant drug patents

EDURANT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2023

(8 days from now)

US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 JANSSEN PRODS Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(7 months ago)

US7638522 JANSSEN PRODS Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
Apr, 2023

(11 days from now)

Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 20 May, 2011

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive patients with hiv-1 rna less than or equal to 100,000 at the start of thearpy; In combination wi...

Dosage: TABLET;ORAL

More Information on Dosage

EDURANT family patents

30

United States

19

European Union

16

Norway

13

Hungary

9

Japan

8

Australia

7

Korea, Republic of

7

China

6

Lithuania

6

Croatia

6

Brazil

6

Spain

5

Denmark

5

Hong Kong

5

Slovenia

5

Luxembourg

4

Israel

4

Mexico

AP

4

AP

4

Portugal

4

Poland

4

Taiwan, Province of China

EA

4

EA

4

Canada

4

New Zealand

3

South Africa

3

Austria

3

Belgium

3

Argentina

3

Cyprus

3

Ukraine

2

Costa Rica

2

Malaysia

2

Nicaragua

OA

1

OA

1

Egypt

1

Jordan

1

Germany

1

Singapore

1

Netherlands

1

RS

1

Panama

1

ME

2. List of Olysio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7671032 JANSSEN PRODS HCV NS-3 serine protease inhibitors
May, 2025

(2 years from now)

US8349869 JANSSEN PRODS Macrocylic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US8754106 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US8741926 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US9040562 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US9856265 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US8148399 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9353103 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US9623022 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

Drugs and Companies using SIMEPREVIR SODIUM ingredient

Market Authorisation Date: 22 November, 2013

Treatment: Method of treating hepatitis c

Dosage: CAPSULE;ORAL

More Information on Dosage

OLYSIO family patents

15

United States

9

European Union

5

Argentina

5

Sweden

5

China

5

Japan

4

Denmark

4

Hong Kong

4

Spain

4

Korea, Republic of

4

Poland

3

Israel

3

South Africa

3

Austria

3

Australia

3

Slovenia

3

Norway

3

Costa Rica

3

Germany

3

Brazil

3

Croatia

3

Portugal

3

Cyprus

3

Malaysia

3

Taiwan, Province of China

3

RS

3

Ecuador

3

Ukraine

EA

3

EA

3

Canada

3

New Zealand

2

Hungary

2

Nicaragua

2

Luxembourg

2

ME

1

El Salvador

1

Uruguay

AP

1

AP

1

Singapore

1

Honduras

1

Guatemala

1

Netherlands

1

Peru

3. List of Prezcobix drug patents

PREZCOBIX's oppositions filed in EPO
PREZCOBIX Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(10 months from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(3 years from now)

US8148374 JANSSEN PRODS Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(1 year, 4 months from now)

US7700645

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Jun, 2027

(4 years from now)

US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Market Authorisation Date: 29 January, 2015

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; Treatment of hiv infection in adults and pediatric patients weighing a...

Dosage: TABLET;ORAL

How can I launch a generic of PREZCOBIX before it's patent expiration?
More Information on Dosage

PREZCOBIX family patents

42

United States

24

European Union

17

Japan

16

Spain

13

Portugal

12

Australia

12

Hungary

12

Korea, Republic of

11

Denmark

11

Slovenia

11

Lithuania

11

Norway

10

Croatia

10

Cyprus

10

China

9

Poland

8

Hong Kong

8

Singapore

EA

8

EA

7

New Zealand

6

Mexico

AP

6

AP

6

Canada

5

Argentina

5

Brazil

5

RS

5

Taiwan, Province of China

5

ME

4

Ukraine

3

Israel

3

South Africa

2

Colombia

2

Ecuador

2

Luxembourg

1

Uruguay

1

Netherlands

1

Peru

1

San Marino

1

Chile

4. List of Prezista drug patents

PREZISTA's oppositions filed in EPO
PREZISTA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(10 months from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(1 year, 4 months from now)

US7700645

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Jun, 2027

(4 years from now)

Drugs and Companies using DARUNAVIR ingredient

Market Authorisation Date: 16 December, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of PREZISTA before it's patent expiration?
More Information on Dosage

PREZISTA family patents

8

United States

6

European Union

4

Spain

3

Denmark

3

Slovenia

3

Portugal

3

Cyprus

2

Australia

2

Korea, Republic of

1

South Africa

1

Mexico

1

Hong Kong

1

Lithuania

1

Hungary

1

Norway

AP

1

AP

1

Brazil

1

Croatia

1

Poland

1

China

1

Japan

EA

1

EA

1

Canada

1

New Zealand

5. List of Symtuza drug patents

SYMTUZA's oppositions filed in EPO
SYMTUZA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(10 months from now)

US7390791 JANSSEN PRODS Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(3 years from now)

US8148374 JANSSEN PRODS Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

US9296769 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US8754065 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 JANSSEN PRODS Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 1 month ago)

US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

US10786518 JANSSEN PRODS Compositions and methods of treating HIV
Jul, 2038

(15 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 17 July, 2018

Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 i...

Dosage: TABLET;ORAL

How can I launch a generic of SYMTUZA before it's patent expiration?
More Information on Dosage

SYMTUZA family patents

65

United States

31

European Union

27

Japan

19

Spain

18

Australia

16

Norway

16

Portugal

15

Hungary

15

Korea, Republic of

14

Denmark

14

Slovenia

14

Lithuania

14

China

13

Croatia

13

Cyprus

11

Hong Kong

11

Poland

11

Canada

11

New Zealand

EA

10

EA

9

Mexico

9

Singapore

AP

8

AP

8

Brazil

6

Argentina

6

RS

6

Taiwan, Province of China

6

Ukraine

6

ME

5

South Africa

4

Israel

3

Colombia

3

Chile

3

Ecuador

3

Luxembourg

2

Morocco

2

Uruguay

2

Netherlands

2

Peru

2

San Marino

2

Czech Republic

OA

1

OA

1

Turkey

1

Belgium

1

Costa Rica

1

Moldova, Republic of

1

Iceland

1

India

1

Bulgaria

1

Estonia

6. List of Yondelis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895557 JANSSEN PRODS Pharmaceutical formulations of ecteinascidin compounds
Jan, 2028

(4 years from now)

US8895557

(Pediatric)

JANSSEN PRODS Pharmaceutical formulations of ecteinascidin compounds
Jul, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
Pediatric Exclusivity (PED) Apr 23, 2023

Drugs and Companies using TRABECTEDIN ingredient

Market Authorisation Date: 23 October, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of YONDELIS before it's patent expiration?
More Information on Dosage

YONDELIS family patents

3

United States

2

Argentina

2

Peru

2

China

1

Israel

1

South Africa

1

Denmark

1

El Salvador

1

Austria

1

Mexico

1

Australia

1

Jordan

1

Russia

1

Slovenia

1

Hong Kong

1

Uruguay

1

Norway

1

Germany

1

Croatia

1

Brazil

1

Honduras

1

Guatemala

1

Portugal

1

Cyprus

1

Malaysia

1

Spain

1

Korea, Republic of

1

Poland

1

RS

1

United Kingdom

1

Taiwan, Province of China

1

Ukraine

1

Japan

1

Canada

1

Panama

1

New Zealand

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic